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Type III galactosemia results from reduced activity of the enzyme UDP-galactose 40-epimerase. Five
disease-associated alleles (G90E, V94M, D103G, N34S and L183P) and three artiﬁcial alleles (Y105C,
N268D, and M284K) were tested for their ability to alleviate galactose-induced growth arrest in
a Saccharomyces cerevisiae strain which lacks endogenous UDP-galactose 40-epimerase. For all of these
alleles, except M284K, the ability to alleviate galactose sensitivity was correlated with the UDP-galactose
40-epimerase activity detected in cell extracts. The M284K allele, however, was able to substantially
alleviate galactose sensitivity, but demonstrated near-zero activity in cell extracts. Recombinant
expression of the corresponding protein in Escherichia coli resulted in a protein with reduced enzymatic
activity and reduced stability towards denaturants in vitro. This lack of stability may result from the
introduction of an unpaired positive charge into a bundle of three a-helices near the surface of the
protein. The disparities between the in vivo and in vitro data for M284K-hGALE further suggest that there
are additional, stabilising factors present in the cell. Taken together, these results reinforce the need for
care in the interpretation of in vitro, enzymatic diagnostic tests for type III galactosemia.
 2011 Elsevier Masson SAS. Open access under CC BY license.1. Introduction
The enzyme UDP-galactose 40-epimerase (GALE) catalyses the
interconversion of UDP-galactose and UDP-glucose. This reaction
occurs in the Leloir pathway of galactose metabolism [1]. In
mammals, and other higher eukaryotes, the enzyme also catalyses
the isomerisation of UDP-N-acetylgalactosamine and UDP-N-ace-
tylglucosamine and thus also plays a vital role in the synthesis of
precursors for glycoprotein and glycolipid synthesis [2]. Mutations
in the corresponding gene leading to reduced expression or enzyme
activity are associated with the genetic disease epimerase-
deﬁciency, or type III, galactosemia [3e11]. This is the least well
understood form of galactosemia, behind type I (galactose 1-
phosphate uridylyltransferase deﬁciency) and type II (gal-
actokinase deﬁciency) [12e15]. All three forms can result in the
development of cataracts during childhood and abnormal levels of
Leloir pathway metabolites in the bloodstream or urine. However
the occurrence, and severity, of other symptoms vary widely. Theseonic acid; gal-1P, galactose 1-
Cl, guanidine hydrochloride;
d cells.
fax: þ44(0)28 9097 5877.
rk.
nder CC BY license.are inﬂuenced by which gene is mutated, the precise mutation
which occurs, other genetic factors that remain poorly understood,
and the patient’s environment (especially diet) [16]. In the most
severe forms of galactosemia acute damage resulting from dietary
exposure to galactose, generally from milk, can be lethal in the
neonatal period. Even in the absence of dietary galactose exposure,
however, patients with severe forms of galactosemia may experi-
ence long-term negative outcomes including cognitive, speech,
ovarian, and other complications. In contrast, patients with the
mildest forms of galactosemia suffer only from cataracts which may
self-resolve upon dietary restriction of galactose, or which can be
resolved by surgery, if needed.
Type III galactosemia was previously categorised into a severe
(or generalised) and a mild (or peripheral) form [3,4]. Recent work
has demonstrated that there are also intermediate forms and that
the disease should be considered as a continuum of phenotypes
dictated by GALE genotype and the level of residual GALE activity
present in key tissues, by other genes present in the patient’s
genome, and by the patient’s environment [17]. Analysis of variant
forms of GALE associated with type III galactosemia showed that
there are a number of biochemical causes of the disease. Reduced
GALE catalytic turnover was commonly observed, as was decreased
structural stability [11,18e20]. In human cells expressing some
disease-associated variants of GALE, the protein aggregated in the
cytoplasm [21].
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expression or from kinetic impairment and/or instability/aggrega-
tion of the protein in key tissues, with an apparent inverse rela-
tionship between degree of residual activity and severity of
outcome. However, there is often a disparity between the level of
GALE impairment detected in red blood cells (RBC) and the levels
detected in other cell types, including transformed lymphoblasts;
clinical severity correlates, roughly, with residual GALE activity
detected in cells other than RBC [16]. Prior studies using a yeast
model with a doxycycline-regulated allele of the endogenous yeast
GALE gene, called GAL10, demonstrated a clear inverse relationship
between the level of Gal10p (GALE) activity detected in cell lysates
and galactose sensitivity of the corresponding cultures [22].
Here we extend prior work, expressing ﬁve previously-reported
patient-derived alleles of human GALE (G90E, V94M, D103G, N34S
and L183P [18,23], and also three novel laboratory-generated variants
(Y105C, N268D, and M284K) in a gal10-null strain of the yeast
Saccharomyces cerevisiae. Our results demonstrate that seven of these
eight variants tested support the previously described inverse rela-
tionship between GALE activity and galactose sensitivity [22].
However, one variant (M284K), contradicted this pattern, appearing
to be active in vivo, but not in vitro. Detailed biochemical analyses of
this variant revealed possible causes of the in vitro/in vivo disparity of
function, and reinforced the concern that standard in vitro enzymatic
assays, as performed inmany clinical laboratories, may be insufﬁcient
to predict fully the in vivo function of some variant alleles.
2. Materials and methods
2.1. Expression of hGALE alleles in yeast
All yeast manipulations were performed according to standard
protocols [24] using haploid strains derived fromW303 (MATa ade2-1
his3-11,15 leu 2-3,112 ura3-1 trp1-1 can1-100 RAD5þ), which was the
kind gift of Dr. Rodney Rothstein, Columbia University, New York, NY,
USA. The plasmids and yeast strains used in this study are listed in
Supplementary Tables S1 and S2, respectively. The plasmids were
constructed by subcloning each hGALE allele into the low copy
number (CEN) plasmid, pMM33, or the high-copy number (2m)
plasmid, pMM195, both of which have been described before
[5,18,20]. The Y105C, N268D, andM284Kmutationswere constructed
using error prone PCR of the wild-type hGALE sequence and subse-
quent insertion into vectors. The plasmids in Supplementary Table S1
were transformed into the yeast strain JFy3835, a gal10-, gal80-
haploid strain also derived fromW303, and the resulting yeast strains
are listed in Supplementary Table S2.
2.2. Western blot analysis
Western blot analyses were performed essentially as described
elsewhere [25]. Yeast cells were grown at 30 C and hGALE was
detected using a rabbit polyclonal antiserum (EU69), raised against
puriﬁed hexahistidine-tagged human epimerase protein, at a dilu-
tion of 1:40,000 or 1:50,000. As a control for loading, a second
antiserum directed against endogenous yeast cyclophilin A [26] was
also included at a dilution of 1:240,000 or 1:120,000. Signals were
visualised by enhanced chemiluminescence (ECL, Amersham Phar-
macia Biotech), using a 1:5000 dilution of a horseradish peroxidase
conjugated secondary antibody directed against rabbit Ig (Amer-
sham Pharmacia Biotech), as recommended by the manufacturer.
2.3. Enzyme activities from soluble yeast lysates
Soluble yeast protein lysates were prepared as follows: cell
pellets from cultures grown in SGE medium deﬁcient in uracil to anOD600 of w1 were washed with water and resuspended in lysis
buffer (20 mM Hepes-KOH, pH 7.5, 1 mM DTT, and 0.3 mgml1
BSA) plus protease inhibitors (complete mini, Roche). Lysis was
carried out by vigorous agitation with 0.5 mm acid-washed glass
beads at 4 C. Lysates were clariﬁed by centrifugation at 13,000 g
for 10 min at 4 C. To remove small metabolites, supernatants were
passed through Bio-Spin 30 columns (Bio-Rad) prior to protein
quantiﬁcation. Protein concentration was determined using the
Bio-Rad protein reagent, as recommended by the manufacturer,
with a BSA standard curve. Samples were stored at85 C until use.
GALE activity in yeast lysates was evaluated by monitoring the
conversion of UDP-galactose to UDP-glucose, at 37 C, as previously
described [27] with slight modiﬁcation. In brief, assays were
stopped by the addition of 237.5 ml ice cold water and immediately
ﬁltered through 0.2 mm nylon micro-spin columns (Corning 8169)
to remove particulates before HPLC analysis.
2.4. Yeast growth studies
Growth curves were performed as previously described [27] in
synthetic medium lacking uracil with 2% glycerol/2% ethanol (SGE-
ura). Log phase cells were diluted back to an OD600 equal to 0.4 and
grown with constant agitation in 96-well plates (NUNC) at 30 C.
OD600 measurements were recorded every 2 h using a micro-plate
reader (Bio-Tek Instruments, Model EL808).
2.5. Studies of galactose 1-phosphate accumulation in yeast
S. cerevisiae JFy3835 expressing either wild-type hGALE, no
hGALE, or M284K-hGALE from a centromeric plasmid backbone
were grown in SGE-ura medium at 28 C until OD600¼1, then
diluted so that OD600¼ 0.05, and allowed to double to OD600¼ 0.1.
Galactose was then added (t¼ 0 h) to the growth medium to a ﬁnal
concentration of 0 or 0.01%. Cells (10 ml) were collected for intra-
cellular metabolite analysis at t¼ 0 h, 12 h, and 24 h. Extracts were
prepared essentially as described previously [27]. In brief, 10 ml of
yeast culture was quenched in 20 ml of 60% (v/v) ice-cold methanol
(MeOH). Yeast cells were collected by centrifugation at 2000 rpm
for 20 min at 4 C, then transferred to microcentrifuge tubes and
washed once with 1 ml of sterile water. Intracellular metabolites
were then extracted by vigorous agitation of the cells for 45 min at
4 C in CHCl3:MeOH:H2O, 4:2:1 (v/v/v), with a ﬁnal volume of
875 ml. The aqueous layer was collected after centrifugation at
2000 rpm for 20 min at 4 C. The remaining organic phase was re-
extracted with 125 ml MeOH and 125 ml water. Aqueous layers were
combined and dried under vacuum without heat. Finally, dried
metabolites were rehydrated with sterile water to a concentration
of 5 mg cell dry mass/ml and ﬁltered through 0.2 mm nylon ﬁlters
(Alltech) before HPLC analysis.
Metabolites were separated and galactose 1-phosphate (gal-1P)
quantiﬁed using a DX600 HPLC system (Dionex, Sunnyvale, CA)
consisting of a Dionex AS50 autosampler, a Dionex GP50 gradient
pump, and a Dionex ED50 electrochemical detector, as previously
described [27]. In brief, carbohydrates were separated on a Carbo-
Pac PA10 column (250 4 mm) with an amino-trap (50 4 mm)
placed before the analysis column and a borate-trap (50 4 mm)
placed before the injector port to remove trace amounts of borate
from the mobile phase buffers. Samples were maintained at 4 C in
the autosampler tray and the chromatography was performed at
room temperature. 20 ml of each sample were injected. The
following mobile phase buffers were used for separation of
carbohydrates: Buffer A, 15 mM NaOH, and Buffer B, 50 mM NaOH/
1 M sodium acetate. The ﬂow rate was maintained at 1 mlmin1.
Buffers were degassed andmaintained under a helium atmosphere.
Gal-1P was detected using a low salt gradient procedure: Gradient
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(8e15 min), a linear increase of B to 50% (15e25 min), hold 50% A
and 50% B (25e30 min), a linear decrease of B to 2% (30e35 min).
Gal-1P was detected by electrical chemical detection using an ED50
detector consisting of a gold electrode and a pH-Ag/AgCl reference
electrode for signal detection by integrated amperometry.
2.6. Expression and puriﬁcation of recombinant proteins
Wild-type human GALE was expressed in, and puriﬁed from,
Escherichia coli as previously described [19]. The codon corresponding
to Met-284 in the expression vector was altered using the Quik
Change protocol [28]. Following veriﬁcation of the DNA sequence
(MWG-Biotech, Ebersburg, Germany), the mutated plasmid was used
to direct the expression of M284K-hGALE. The conditions for
expression and puriﬁcationwere essentially the same as for the wild-
type protein, except that the cells were grown at 24 C.
The coding sequence for human UDP-glucose dehydrogenase
was ampliﬁed by PCR from IMAGE clone [29] number 3916854 using
primers which incorporated NcoI and XhoI restriction sites at the 50
and 30 ends of the sequence, respectively. The PCR product was
digested with NcoI and XhoI and inserted into pET21d which had
been previously cut with the same enzymes. The sequence of the
recombinant expression vector was veriﬁed. This plasmid was then
transformed into E. coli Rosetta (Novagen). Single colonies resulting
from this transformation were picked and grown in 5 ml of LB
(supplemented with 100 mgml1 ampicillin and 34 mgml1 chlor-
oamphenicol), shaking at 37 C overnight. This culture was then
diluted into 1 l of LB (supplementedwith 100 mgml1 ampicillin and
34 mgml1 chloroamphenicol) and grown shaking at 37 C until
A600nm was between 0.6 and 1.0 (typically 3 h). At this point the
culture was induced with 2 mM IPTG and grown for a further 3 h.
Cells were harvested by centrifugation (4200 g for 20 min),
resuspended in buffer R (50 mMHepes-NaOH, pH 7.5, 150 mMNaCl,
10 %(v/v) glycerol) and frozen at 80 C until required.
The cell suspensions were thawed and disrupted by sonication
on ice (three 30 s pulses of 100W with 30 s gaps in between for
cooling). The extract was centrifuged (20,000 g for 20 min) to
remove insoluble material and the supernatant applied to a 1 ml
nickel agarose (Sigma, Poole, UK) column. Once this solution had
passed through, the column was washed with 20 ml buffer W (as
buffer R, expect with 500 mM NaCl) and the protein eluted with
three 2 mlwashes of buffer E (bufferW supplementedwith 250 mM
imidazole). Protein containing fractions were identiﬁed by SDS-
PAGE (Supplementary Fig. S1) and dialysed overnight at 4 C
against buffer D (buffer R supplemented with 2 mM DTT). The
protein concentrationwas estimated by themethod of Bradford [30]
using bovine serum albumin as a standard. The protein solutionwas
divided into 100e200 ml aliquots and stored frozen at 80 C.
2.7. Measurement of the steady state kinetic parameters for UDP-
galactose 40-epimerase
Enzyme activity was measured by coupling the production of
UDP-glucose to the oxidation of this compound by NADþ catalysed
by UDP-glucose dehydrogenase [31]. Reactions (150 ml) were set up
in triplicate in 96 well plates. Each well contained 10 mM HEPES-
NaOH, pH 8.8, 10 mM NADþ and a variable amount of UDP-
galactose. Plates were preincubated for 5 min at 37 C, and then
1.2 mM recombinant human UDP-glucose dehydrogenase was
added. To initiate the reaction, wild-type hGALE or M284K-hGALE
was added to a ﬁnal concentration of 5 nM and 1000 nM respec-
tively. All reactions were monitored at 340 nm for 20 min at 37 C
using a Multiskan Spectrum spectrophotometer (Thermo Scien-
tiﬁc). Controls containing no hGALE were routinely used andalways gave no detectable rate. Initial rates of NADH production
were calculated from the linear portions of the progress curves.
These rates (v) were then plotted against substrate concentration
and the data ﬁtted to the following equations using non-linear
curve ﬁtting [32] as implemented in the program GraphPad Prism
(GraphPad Software, CA, USA). All points were weighted equally.
v ¼ Vmax½UDP galactose=Km þ ½UDP galactose (1)
where Vmax is the maximum, limiting rate and Km is the Michaelis
constant [33]
v ¼ Vmax½UDP galactoseh=Kh0:5 þ ½UDP galactoseh (2)
where h is the Hill coefﬁcient and K0.5 is the concentration of
substrate to give a rate equal to half of Vmax [34].
The goodness of ﬁt to these equations was compared using the F
test and results are reported for the best ﬁt to the data.
2.8. Limited proteolysis
Wild-type hGALE or M284K-hGALE (10 mM) was incubated at
37 C for 5 min with and without 1 mM UDP-galactose. Trypsin
(Sigma) was then added to a ﬁnal concentration of 600 nM and
permitted to digest the protein for 30 min. Digestion was then
halted by the addition of an equal volume of SDS loading buffer
(125 mM triseHCl, pH 6.8, 4% (w/v) SDS, 20% (v/v) glycerol,1% (w/v)
dithiothreitol, 0.002% (w/v) bromophenol blue) and denaturation
at 95 C. Samples were then analysed by 15 % SDS-PAGE.
2.9. ANS unfolding assay
Wild-type hGALE or M284K-hGALE (2.3 mM dissolved in buffer
D) in the presence or absence of 50 mM UDP-galactose were mixed
with increasing concentrations of GuHCl (0e4 M, 0.5 M increments,
dissolved in 10 mMHepes-NaOH, pH 7.5). Experiments were set up
in triplicate in 96 well plates and incubated at 4 C for 2 h. The
extrinsic hydrophobic ﬂuorophore ANS (Sigma) was then added to
the samples to a ﬁnal concentration of 70 mMand samples were left
to incubate at 4 C for a further 1 h. These reactions were set up
alongside controls in which protein was omitted. Fluorescence was
then detected in a Spectra Max Gemini X (Molecular Devices)
ﬂuorimeter (excitation at 370 nm and emission at 480 nm). The
mean ﬂuorescence was then plotted against GuHCl concentration.
3. Results
3.1. Expression of patient and laboratory-generated alleles of hGALE
in a null-background strain of yeast
To test whether differentially impaired alleles of hGALE would
conform to the inverse relationship previously deﬁned between
GAL10 (yeast GALE) expression and galactose-sensitivity in yeast [22]
we expressed each of ﬁve different patient-derived alleles (N34S,
G90E, V94M, D103G, and L183P) and three laboratory-generated
alleles (Y105C, N268D, and M284K) in a previously described gal10-
null strain of S. cerevisiae, JFy3835 [35]. Each of the ﬁve patient-
derived alleles has been demonstrated previously to encode either
near-normal, low level, or undetectable levels of GALE activity [18,23],
and all three laboratory-generated alleles, which resulted from
a random mutagenesis screen for ostensibly temperature-sensitive
alleles (see Materials and methods), were novel and previously
uncharacterised. Each of these eight hGALE alleles was expressed
individually from a strong constitutiveGAP promoter in a centromeric
plasmid in the yeast JFy3835, and lysates of the resulting trans-
formants were characterised by Western blot to reveal abundance of
a
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apparent GALE speciﬁc activity level (Fig. 1).
Of the hGALE variant alleles tested, all but one (M284K) demon-
strated clearly detectable hGALE proteinwhen expressed froma low
copy (CEN) plasmid, although there was some variation in abun-
dance (Fig. 1a). Of note, M284K-hGALE protein was detected by
Western blot when expressed from a high copy plasmid (Fig. 1a).
Given that all of the hGALE proteins were expressed in these
transformants from centromeric plasmids bearing the same regu-
latory sequences, we conclude that the apparent differences in
expression level between alleles likely reﬂect differences in pro-
cessing or stability of the encoded messages or proteins. Of course,
given that ourWestern blotswere performed on soluble cell lysates,
we cannot rule out the possibility that during lysate preparation the
M284K-hGALE protein became insoluble rather thanwas degraded.
GALE activity assays performed on soluble lysates from null-
background yeast expressing each of the eight variant hGALE
alleles (see Materials and methods) demonstrated considerable
variation in apparent speciﬁc activity relative to controls (Fig. 1b).
The N34S, D103G, and N268D proteins all demonstrated above 50%
residual activity under the conditions tested; the Y105C protein
demonstrated just over 10%, and the V94M and L183P proteins each
demonstrated less than 5% residual activity. The G90E and M284K
proteins each demonstrated no statistically signiﬁcant GALE activity
detectable above the null control.b
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L183P3.2. The anticipated relationship between hGALE function in vitro
and in a yeast model system was demonstrated for most
but not all alleles
As demonstrated previously (e.g. [18,20]), GALE deﬁcient yeast
growth-arrest in the presence of as little as 0.002% galactose, andFig. 1. Abundance and activity of hGALE proteins expressed in a null-background
strain of yeast. (a) Soluble lysates from yeast expressing the indicated alleles of
hGALE from low copy number (MM33) or high copy number (MM195) plasmids were
subjected to Western blot analysis (see Materials and methods) with antisera speciﬁc
for hGALE and the endogenous yeast protein cyclophilin A, which served as a loading
control. (b) Soluble lysates from yeast expressing the indicated alleles of hGALE were
assayed for epimerase activity as described in Materials and methods. Values represent
the means SEM (n¼ 3) of activity normalised to the wild-type control. An asterisk (*)
denotes GALE activity that is statistically signiﬁcant from the negative control using
a one-tailed t-test (p< 0.05).expression of wild-type human GALE is sufﬁcient to rescue this
phenotype. Previously we have also demonstrated that expression
of severely impaired patient alleles, such as G90E, V94M or L183P
[5,18,23], largely fails to rescue the galactose-sensitivity of other-
wise GALE-deﬁcient yeast, while expression of mildly impaired
alleles, such as N34S, D103G, K257R or G319E largely rescues
[5,23,35]. Here we use ﬁve of those alleles as controls, while testing
the impact of expressing three novel alleles: Y105C, N268D and
M284K.c
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Fig. 2. Growth and gal-1P accumulation in S. cerevisiae Dgal10 expressing wild-type or
variant alleles of hGALE from centromeric plasmids. Yeast cells were grown at 30 C in
SGE-ura medium supplemented with (a) 0.002% (w/v) or (b) 0.01% (w/v) galactose.
Growth was monitored by measurement of the optical density at 600 nm (OD600). All
strains grew normally in SGE-ura medium without galacose (not shown). (c) Intra-
cellular gal-1P levels in JFy3835 yeast expressing wild-type hGALE (wt), no GALE (bb),
or M284K-hGALE (M284K). Cultures grown in SGE-ura medium were supplemented
with 0.01% galactose at t¼ 0; samples were harvested for analysis of intracellular gal-
1P as described in Materials and Methods at t¼ 0 h, t¼ 12 h, and t¼ 24 h. Values
plotted represent mean SEM, n¼ 3. The level of gal-1P detected in “bb” samples at
12 h and 24 h was statistically distinct from the corresponding values detected in wild-
type or M284K samples by two-tailed Student t-test, p< 0.001. Note no gal-1P was
detected at any time points in control cultures not supplemented with galactose (data
not shown).
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Fig. 3. Expression and puriﬁcation of M284K-hGALE from E. coli. Expression levels in
cells grown at 37 C (a) and at 24 C (b) were monitored by SDS-PAGE (10%), stained
with Coomassie blue. Greater amounts of the protein could be produced when the cells
were grown at 24 C; however, even at this temperature some degradation is evident.
In both (a) and (b) U, extract from cells immediately prior to induction; I, extract from
cells at the end of the period of induction prior to harvesting; S, the supernatant
remaining after sonication and centrifugation of the cells; F, the material passing
through the column; E1 and E2, the ﬁrst and second elutions respectively; M,
molecular mass markers (kDa).
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(Fig. 1), N268D-hGALE is expressed well and retains >60% residual
activity, Y105C-hGALE is expressed well and retains >10% residual
activity, and M284K-hGALE accumulates in cells only to very low
levels and demonstrates no detectable GALE activity. From prior
studies [22], we would have predicted that otherwise GALE-deﬁcient
yeast expressing N268D-hGALE or Y105C-hGALE would grow well
despite the presence of 0.002% or even 0.01% galactose in their
medium, and that is what we observed (Fig. 2). None of the variants0 200 400 600 800 
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Fig. 4. The M284K variant has lower enzymatic activity than does wild-type hGALE. The stea
are shown. Each point represents the mean of three independent determinations of the ra
reactions were carried out at 37 C and 24 C in the presence of 1.2 mM coupling enzyme (affected growth in SGE-ura medium lacking galactose (data not
shown). Wewould also have predicted that otherwise GALE-deﬁcient
yeast expressing M284K-hGALE would not grow well in the presence
of 0.002% or 0.01% galactose, but that is not what we observed
(Fig. 2a,b). Instead, the yeast expressingM284K-hGALE grewaswell in
the presence of galactose as did strains expressing wild-type or
mildly-affected alleles of hGALE. Further, as predicted from their
growth, yeast expressing M284K-hGALE as their only GALE demon-
strated no apparent accumulation of gal-1P despite exposure to 0.01%
galactose (Fig. 2c), further implicating the M284K allele as functional
in vivo. In short, M284K-hGALE did not behave according to the
anticipated relationship between activity in vitro and in vivo. To
explore the basis for this unexpected result, we pursued detailed
biochemical studies of recombinant M284K-hGALE.
3.3. Biochemical properties of recombinant M284K-hGALE
Given the unusual behaviour of the M284K variant in the yeast
model, we decided to investigate its properties further. Prior studies
had shown that the wild-type and many variant forms of hGALE
could be expressed in, and puriﬁed from, E. coli cells grown at 37 C
[19,20]. This was not the case with the M284K variant and virtually
no protein was produced using this protocol (Fig. 3a). However,
when the cells were grown at 24 C, a detectable amount of hGALE
was puriﬁed (Fig. 3b). Although theM284K-hGALE protein appeared
to be expressed at similar levels to its wild-type counterpart, it
tended to precipitate on dialysis, reducing overall yields.
The M284K variant demonstrated altered kinetic properties
compared to recombinant wild-type hGALE. The Vmax was
decreased approximately 24-fold at 37 C (Fig. 4 and Table 1).
Similar effects were also observed at 24 C (Table 1). Interestingly,
the rate of reaction catalysed by the variant exhibited a sigmoidal
dependence on substrate concentration at both temperatures. The
wild-type enzyme only exhibited this behaviour at the lower
temperature (Fig. 4 and Table 1).
The variant was also much less stable than the wild-type
protein. Limited proteolysis assays showed that this variant was
almost completely digested under conditions where the wild-type
protein was cleaved into discrete fragments (Fig. 5a). In contrast to
thewild-type protein, the substrate (UDP-galactose) did not protectC ° 4 2 
0 250 500 750 1000 1250 1500 
0 
1 
2 
3 
4 
[UDP-Gal]/ M 
S
p
e
c
i
f
i
c
 
R
a
t
e
/
 
m
o
l
 
U
D
P
-
G
l
c
.
m
i
n
 
.
m
g
 
0 250 500 750 1000
0.00 
0.25 
0.50 
[UDP-Gal]/ M 
S
p
e
c
i
f
i
c
 
R
a
t
e
/
 
m
o
l
 
U
D
P
-
G
l
c
.
m
i
n
 
.
m
g
 
dy state enzyme kinetics for (a) 5 nM wild-type and (b) 1000 nM M284K variant GALE
te and the error bars represent the standard deviations of these means. In both cases,
UDP-glucose dehydrogenase) and 10 mM NADþ at pH 8.8.
Table 1
Kinetic constants of recombinant wild-type and M284K variant hGALE enzymes.
Protein Temperature,
C
Km or K0.5,
mM
Vmax, mmol
UDP-Glcmin1mg1
h
hGALE 37 48 16 22 2 n/a
hGALE 24 380 48 4.0 0.3 1.7 0.2
M284K-hGALE 37 250 18 0.91 0.04 1.7 0.1
M284K-hGALE 24 200 16 0.46 0.02 2.0 0.3
T.J. McCorvie et al. / Biochimie 93 (2011) 1747e17541752M284K-hGALE from this digestion (Fig. 5a). The structural stability
of M284K was further investigated using the hydrophobic ﬂuo-
rophore 1-anilinonaphthalene-8-sulphonic acid (ANS). This
compound binds to exposed hydrophobic patches on proteins; this
binding results in an increase in ANS ﬂuorescence. Typically ANS
binds weakly to fully folded, globular proteins which have their
hydrophobic residues largely in the interior. However, as unfolding
begins (for example, in response to a denaturing agent) hydro-
phobic patches are exposed. As the process continues, and the
partially folded protein is converted to a random coil, fully unfolded
polypeptide, these hydrophobic regions are disrupted and ANS
binding often decreases [36]. The compound has been shown to
bind at, or near, the active site of E. coli GALE [37]. Wild-type hGALE
exhibited a typical unfolding proﬁle in the presence of increasing
concentrations of guanidine hydrochloride (GuHCl) withmaximum
ANS binding at approximately 0.8 M GuHCl. Addition of the
substrate, UDP-galactose (50 mM), stabilised the wild-type protein
and shifted the concentration of GuHCl required for maximum
binding of ANS to approximately 1.6 M (Fig. 5b,c). In contrast, the
M284K variant showed no binding to ANS in the presence or
absence of substrate over the range of GuHCl concentrations tested
(0e4M). Loss of interaction with ANS upon denaturation has also
been demonstrated with Kluyveromyces fragilis GALE [38].
4. Discussion
We report here a combination of in vitro and in vivo studies of
eight variant alleles of human GALE e ﬁve patient-derived and
three resulting from a laboratory-based mutagenesis screen. Our0 1 2 3 4
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Fig. 5. Limited proteolysis of wild-type hGALE and the M284K variant showed greater degra
protected the wild-type protein, but not the M284K variant from proteolysis. C, control, un
with 600 nM trypsin in the presence of 1 mM UDP-galactose. (b) Guanidine hydrochloride
UDP-galactose (left), a peak occurred at approximately 0.8 M GuHCl. This peak shifted to app
were seen with the M284K variant. The control data represent the ﬂuorescence of ANS in in
mean of three determinations and the error bars represent the standard deviations of thesresults demonstrate that seven of the eight alleles followed the
previously-predicted relationship between in vitro and in vivo
function, but one, M284K, did not. That two of three “artiﬁcial”
hGALE alleles demonstrated the same apparent relationship
between in vitro and in vivo function as was seen for the ﬁve
patient-derived alleles suggests that similar exceptions might also
exist among naturally-occurring alleles. Naturally-occurring alleles
that function well in vivo are unlikely to come to clinical attention,
however, and therefore may not be recognised.
Kinetic and stability studies of recombinant M284K-hGALE
revealed a protein compromised in both parameters. The low
enzymatic activity, tendency to precipitate, high susceptibility to
proteolysis and lack of ANS binding of M284K-hGALE all suggested
that this variant is largely unfolded in solution in vitro. However, its
ability to complement a Dgal10 yeast strain, demonstrates that it
can function in vivo. Thus, for this variant, in vitro analysis is a poor
predictor of in vivo function, and one must conclude that the
protein instability may be limited to in vitro contexts. Potentially
critical differences between the in vitro and in vivo environments
are innumerable, and range from issues such as net protein
concentration to the presence of chaperones in vivo (which may
help maintain a structurally unstable variant in a folded, soluble,
active form) and even the possibility that the Leloir pathway
enzymes may be organised into a supra-molecular complex (or
metabolon) [39]. Interactions with the other proteins, including
other Leloir pathway enzymes, in theory might help to reinforce
and stabilise the structure of GALE in vivo. Of course, the prepara-
tion of a cell lysate, especially frommicrobes with cell walls, such as
bacteria or yeasts, would likely disrupt these interactions, thereby
destabilising the M284-hGALE protein and leading to the Western
blot and enzyme activity results presented here. Wild-type hGALE
would similarly lose its potentially stabilising interactions or
inﬂuences, but it might be sufﬁciently resilient to withstand the
loss. While the nature of the in vivo “GALE stabilizing factor or
factors” remains unclear, the results reported here suggest that
these factors are likely to be conserved between yeast and humans.
It would be interesting to extend our experiments to express
M284K-hGALE and other alleles of human GALE in the null-0 1 2 3 4
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0
Control
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dation of the M284K variant compared to the wild-type protein. UDP-galactose partially
digested protein (10 mM); P, protein digested with 600 nM trypsin; U, protein digested
denaturation of the wild-type protein followed by ANS ﬂuorescence. In the absence of
roximately 1.6 M GuHCl in the presence of 50 mM UDP-galactose (right). No such effects
creasing concentrations of GuHCl in the absence of protein. Each point represents the
e means.
Fig. 6. Met-284 is located towards the surface of the protein, away from the active site and NADþ binding site. The left hand ﬁgure shows the location of this residue (circled) in both
subunits of the hGALE homodimer. The right hand view shows a close-up of the residue in one subunit. The side chain of Met-284 (circled) points towards the centre of a bundle of
three a-helices. Substitution of this residue for lysine will insert an unpaired positive charge into this bundle. The ﬁgures were made in PyMol (www.pymol.org) using PDB entry
1EK6 [41].
T.J. McCorvie et al. / Biochimie 93 (2011) 1747e1754 1753background mammalian cell line, ldlD, as has been described
previously for wild-type human GALE and E. coli GALE [40], as well
as a set of patient alleles [21]. Of note, even in this mammalian
expression system aggregation of some disease-associated variants
of GALE has been observed [21]. For the M284K variant it would be
especially interesting to quantify synthesis level, stability, local-
isation, and possible aggregation, to see if higher levels of soluble,
active M284K-hGALE protein might be detected in a mammalian
system. Such experiments would also permit extracts to be
prepared and the activity of the protein derived from this source to
be assessed in vitro.
The existence of a high resolution crystal structure for hGALE
[2,41] enables some speculation about the structural consequences
of altering methionine to lysine at position 284. The residue is
located far from the dimer interface and is part of an a-helix on the
surface of the protein (Fig. 6). The side chain points towards the
centre of a triple helix bundle and the change to lysine, with the
consequent introduction of an unpaired positive charge, is likely to
disrupt the packing of this helix bundle. That this substitution has
such profound consequences for the stability of the whole protein,
suggests that this a-helical bundle may be a key structure in the
folding pathway of the protein. Furthermore, if interactions with
other proteins do help stabilise hGALE in vivo, then they are likely to
occur close to this region.
The observation of non-MichaeliseMenten behaviour by the
M284K variant (and thewild-type enzyme at reduced temperature)
is interesting. Although this behaviour by the wild-type human
enzyme at 37 C has not been previously reported, there is
considerable evidence for allostery in GALE isolated from the yeast
K. fragilis [42e45]. At present, the consequences of this allostery in
the human enzyme are not clear. That no (or limited) allostery is
observed in the isolated wild-type enzyme at 37 C suggests that
there may be only speciﬁc circumstances in vivo under which it is
more pronounced. For example, it is possible that, like in many
other metabolic enzymes, hGALE’s activity can be regulated by
small molecule effectors. It is also possible that, like in K. fragilis, the
allostery is more pronounced in the reverse reaction.
The results reported here demonstrate that biochemical tests on
hGALE in vitro will not always predict behaviour in vivo. For the
majority of variants investigated, there was a clear correlation
between their ability to complement galactose sensitivity of the
Dgal10 yeast strain and the enzymatic activity in cell extracts. This
was not the case with the M284K variant which was functional in
the context of a living yeast cell, but compromised as an isolated
protein, or in a soluble cell-free lysate. This ﬁnding emphasises the
need to investigate the properties of newly discovered hGALE
variants both in vitro and in model in vivo systems.Acknowledgements
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